The first phase III study of tumor-infiltrating lymphocytes in melanoma shows that the cells are more effective than ipilimumab. Compared with the CTLA4 inhibitor, tumor-infiltrating lymphocytes yielded a higher objective response rate and longer progression-free and overall survival.

You do not currently have access to this content.